Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder

By: via Benzinga
Clearside Biomedical Inc(NASDAQ: CLSD) announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.